Business news from Ukraine


5 August , 2020  

Biopharma pharmaceutical company (Kyiv) has accumulated about 150 liters of plasma from 118 donors who have had coronavirus (COVID-19) for the production of the drug for COVID-19, and the same amount is needed to create an experimental series.
The company informed Interfax-Ukraine that it is necessary to collect 300 liters to create the first experimental series of drugs.
“Not everyone who is diagnosed has developed antibodies, but they are the main weapon against the disease. However, there are cases of asymptomatic course of the disease. That is why everyone who donate plasma in our centers is tested for antibodies to COVID-19,” said the president of the company, Kostiantyn Yefymenko.
He called on Ukrainians, representatives of government, business and public activists to help attract donors who have overcome the coronavirus.
He said that if antibodies are detected, the collected plasma is used to create a drug for coronavirus, if there are no antibodies, then other drugs are made from donated blood.
Biopharma also reports that clinical trials of use of Bioven in the symptomatic treatment of coronavirus are completed. This drug is also produced from donated plasma. In particular, according to the company, during the Bioven research, Ukrainian and international experts noted that it reduces the severity of the cytokine storm and helps stabilize the condition of seriously ill patients.
“The preliminary results of the studies are extremely encouraging: everyone who took Bioven, observe the stabilization of the general condition up to two days after taking the drug, followed by a decrease in manifestations of respiratory failure,” the company reported.
As reported, clinical effectiveness trials of domestic drugs AMIZON MAX (produced by Farmak), Amiksin IC (Interchem), Bioven (Biopharma) and Corvitin (BHFZ) are underway in Ukraine.

, , , ,